Cell treatment via liver artery catheter for alcoholic cirrhosis
Part of Digestive system clinical trials.
This Phase 3 trial tests whether a cell medicine called Cellgram-LC, delivered through a catheter into the liver artery, is safer and works better for people with alcoholic cirrhosis. It may help improve outcomes in people with more advanced liver scarring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 19 or 70 (the study uses a wide age range, but you must be within it).
- You have alcoholic cirrhosis that has been confirmed, and your liver severity is Child-Pugh B or C (score 7 or higher).
- Your doctors estimate you can live more than 1 year.
- You’re able to have a catheter placed in your liver artery for treatment.
- If you can become pregnant, your pregnancy test must be negative and you must use approved birth control during the study.
- You can follow the study plan and agree in writing to join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks on people who previously received Cellgram-LC for alcohol-related liver cirrhosis (liver scarring) in an earlier trial. It helps researchers learn long-term safety and outcomes after that treatment.
This Phase 2 study tests whether SAMe can help people with alcoholic cirrhosis (scarred liver) who are in early to mid stages. It may also include healthy volunteers to compare safety and blood/body measurements.
This trial tests if injecting donated liver cells into the main artery feeding the liver can help people with decompensated cirrhosis. It aims to see if this treatment is safe and might improve liver function.
This trial tests whether a type of stem cell therapy is safe for people with liver cirrhosis caused by alcohol, hepatitis B, or hepatitis C. It may help if your liver disease is controlled and you have moderate to severe cirrhosis.
This trial tests a new cell injection called HCL001 for people with decompensated cirrhosis (advanced liver scarring causing complications). The goal is to see if it's safe and helps improve liver function. It may be an option if you've tried standard treatments and meet specific health criteria.
This study tests an injection called CUD005 for people with advanced liver cirrhosis that is causing complications. The goal is to see if it is safe and can help improve liver function.
Hear when a new Alcoholic Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.